Immunome Inc.
IMNMAs of the close on Sep 25, 2026
Price
$21.41
Market cap
$2.43B
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Immunome Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Immunome Inc. — 10-K filed Mar 3, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 29, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Legal & General Group Plc | 2026-03-31 | 81,588 | $1.78M | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 206,799 | $4.52M | SEC filing |
| HUNTINGTON NATIONAL BANK | 2026-03-31 | 1 | $22 | SEC filing |
| ASSETMARK, INC | 2026-03-31 | 4,535 | $99.2K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 2,560,664 | $56M | SEC filing |
| VICTORY CAPITAL MANAGEMENT INC | 2026-03-31 | 47,360 | $1.04M | SEC filing |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2026-03-31 | 1,097,836 | $24M | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 1,999 | $44.9K | SEC filing |
| INTECH INVESTMENT MANAGEMENT LLC | 2026-03-31 | 31,038 | $679K | SEC filing |
| Sterling Investment Advisors, Ltd. | 2026-03-31 | 9,918 | $217K | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 8,066 | $176K | SEC filing |
| Sofinnova Investments, Inc. | 2026-03-31 | 1,701,904 | $37.2M | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 163,450 | $3.51M | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2026-03-31 | 11,051 | Not shown | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 899,146 | $19.7M | SEC filing |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 808,019 | $17.7M | SEC filing |
| Smartleaf Asset Management LLC | 2026-03-31 | 182 | $3.51K | SEC filing |
| Three Bridge Wealth Advisors, LLC | 2026-03-31 | 37,615 | $823K | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 60,498 | $1.32M | SEC filing |
- Each value is checked against Immunome Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Immunome Inc.'s share price.
- 1 row left out: the value per share it reports is far from Immunome Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so it may describe another security or share class.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Immunome Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-02 · Rosett Max: Larger than 12 of the 13 other insider sales of Common Stock on file. SEC filing
- 2025-12-22 · Barchas Isaac: Larger than all 13 other insider sales of Common Stock on file. SEC filing
- 2025-03-26 · SIEGALL CLAY B: Larger than 39 of the 41 other insider purchases of Common Stock on file. SEC filing
- 2025-01-31 · SIEGALL CLAY B: Larger than 40 of the 41 other insider purchases of Common Stock on file. SEC filing
- 2024-05-20 · SIEGALL CLAY B: Larger than 37 of the 41 other insider purchases of Common Stock on file. SEC filing
- 2023-10-02 · SIEGALL CLAY B: Larger than all 41 other insider purchases of Common Stock on file. SEC filing
- 2020-10-06 · RAPP MICHAEL: Larger than 38 of the 41 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-12-18–2025-12-19: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2025-03-24–2025-03-26: 4 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
- 2024-11-21–2024-11-22: 4 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
- 2024-05-20–2024-05-21: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-10-02–2023-10-02: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2021-05-24–2021-05-26: 10 event(s) across 5 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-25 | Lechleider Robert · Chief Medical Officer | Common Stock | S — Open market or private sale | −14,420 | 20.66 | SEC filing |
| 2026-06-25 | Lechleider Robert · Chief Medical Officer | Common Stock | S — Open market or private sale | −40,580 | 19.56 | SEC filing |
| 2026-06-15 | Rosett Max · Chief Financial Officer | Common Stock | S — Open market or private sale | −60,000 | 18.23 | SEC filing |
| 2026-06-05 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +3,500 | 19.46 | SEC filing |
| 2026-06-05 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +6,000 | 19.48 | SEC filing |
| 2026-06-05 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +1,000 | 19.27 | SEC filing |
| 2026-06-05 | BIENAIME JEAN JACQUES · Director | Common Stock | S — Open market or private sale | −10,000 | 19.41 | SEC filing |
| 2026-06-05 | BIENAIME JEAN JACQUES · Director | Common Stock | S — Open market or private sale | −500 | 19.44 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-25 | Lechleider Robert · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +55,000 | SEC filing |
| 2026-06-25 | Lechleider Robert · Chief Medical Officer | Employee Stock Option (right to buy) | M — Exercise or conversion of derivative security | −55,000 | SEC filing |
| 2026-06-15 | Rosett Max · Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +60,000 | SEC filing |
| 2026-06-15 | Rosett Max · Chief Financial Officer | Stock Option (right to buy) | M — Exercise or conversion of derivative security | −60,000 | SEC filing |
| 2026-06-10 | SCHAFER CAROL · Director | Director Stock Option (right to buy) | A — Grant, award, or other acquisition | +9,897 | SEC filing |
| 2026-06-10 | Barchas Isaac · Director | Director Stock Option (right to buy) | A — Grant, award, or other acquisition | +9,897 | SEC filing |
| 2026-06-10 | Boylan James P · Director | Director Stock Option (right to buy) | A — Grant, award, or other acquisition | +9,897 | SEC filing |
| 2026-06-10 | SWAIN SANDRA M · Director | Director Stock Option (right to buy)` | A — Grant, award, or other acquisition | +9,897 | SEC filing |
Showing 8 of 25 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.